Salidroside represses proliferation, migration and invasion of human lung cancer cells through AKT and MEK/ERK signal pathway
Source abstract
Abstract
Salidroside, a glycoside of tyrosol, is isolated from Rhodiola rosea and shows anti-cancer functions in several cancers. However, the potentials of salidroside in the migration and invasion of lung cancer cells and its underlying mechanisms remain unknown. We aimed to investigate the functions and mechanisms of salidroside in non-small cell lung cancer (NSCLC). Human NSCLC cell line A549 was treated with different doses of salidroside. Cell viability, colony formation, apoptosis, migration and invasion were detected by CCK-8, crystal violet-staining assay, flow cytometry and transwell assay, respectively. qRT-PCR and western blot analysis were performed to assess the regulatory effects of salidroside on miR-195 expression and the activation of AKT and the MEK/ERK signal pathway. We found that, salidroside remarkably reduced cell viability, colony formation and Cyclin D1 expression, but increased p21 expression and apoptosis in A549 cells. Additionally, salidroside inhibited the migration and invasion of A549 cells by regulating expressions of migration- and invasion-related proteins. Finally, salidroside inhibited phosphorylation of AKT, MEK and ERK by upregulating miR-195 expression in A549 cells. In conclusion, salidroside inhibited the survival, migration and invasion of NSCLC cells. Salidroside blocked AKT and the MEK/ERK signal pathway by upregulating miR-195 expression in A549 cells.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Medicinal Plants and Bioactive Compounds · Flavonoids in Medical Research · Apelin-related biomedical research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Oncology, Jining No.1 People’s Hospital
Department of Chinese Medicine, Jining No.1 People’s Hospital
Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University
References (40)
Show source-provided references
1. 10.1016/j.ccm.2011.09.00110.1016/j.ccm.2011.09.001 ↗
2. Ridge CA, Mcerlean AM, Ginsberg MS. Epidemiology of lung cancer. Chest. 2003;123:93–98.
3. Cancer UK. Lung cancer survival statistics. 2015.
4. Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park, NY). 2008;22:1486–1492.
5. 10.1200/JCO.2008.17.716210.1200/JCO.2008.17.7162 ↗
6. Kelly GS. Rhodiola rosea: a possible plant adaptogen. Altern Med Rev. 2001;6:293.
7. 10.1002/ptr.201310.1002/ptr.2013 ↗
8. 10.3892/mmr.2013.146810.3892/mmr.2013.1468 ↗
9. 10.1016/j.phymed.2008.07.01310.1016/j.phymed.2008.07.013 ↗
10. 10.1007/s00011-012-0545-410.1007/s00011-012-0545-4 ↗
11. 10.3390/molecules17101148410.3390/molecules171011484 ↗
12. 10.1016/j.jep.2010.09.02510.1016/j.jep.2010.09.025 ↗
13. 10.1016/j.bbrc.2010.06.03310.1016/j.bbrc.2010.06.033 ↗
14. 10.1002/mc.2078010.1002/mc.20780 ↗
15. Sun KX, Xia HW, Xia RL. Anticancer effect of salidroside on colon cancer through inhibiting JAK2/STAT3 signaling pathway. Int J Clin Exp Pathol. 2015;8:615.
16. 10.1016/j.phymed.2011.09.07010.1016/j.phymed.2011.09.070 ↗
17. 10.1016/j.ejphar.2007.01.08910.1016/j.ejphar.2007.01.089 ↗
18. Zhang Y, Yao Y, Wang H, et al. Effects of salidroside on glioma formation and growth inhibition together with improvement of tumor microenvironment. Chinese J Cancer Res. 2013;25:520.
19. 10.1007/s10565-010-9159-110.1007/s10565-010-9159-1 ↗
20. 10.3892/ol.2014.186310.3892/ol.2014.1863 ↗
21. 10.1111/j.1582-4934.2005.tb00337.x10.1111/j.1582-4934.2005.tb00337.x ↗
22. 10.1023/A:102378111456810.1023/A:1023781114568 ↗
23. 10.1007/s13277-014-2153-010.1007/s13277-014-2153-0 ↗
24. 10.18632/oncotarget.325510.18632/oncotarget.3255 ↗
25. 10.1021/np040106y10.1021/np040106y ↗
26. 10.1021/np200906s10.1021/np200906s ↗
27. 10.1634/theoncologist.12-8-92710.1634/theoncologist.12-8-927 ↗
28. 10.1101/gad.7.5.81210.1101/gad.7.5.812 ↗
29. 10.1007/1-4020-7847-1_1110.1007/1-4020-7847-1_11 ↗
30. 10.4161/cbt.7210.4161/cbt.72 ↗
31. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993;8:2127–2133.
32. 10.1073/pnas.90.19.902610.1073/pnas.90.19.9026 ↗
33. 10.1158/0008-5472.CAN-04-399510.1158/0008-5472.CAN-04-3995 ↗
34. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004;1705:69–89.
35. Braicu EI, Gasimli K, Richter R, et al. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer – results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial. Anticancer Res. 2014;34:385–391.
36. 10.1038/embor.2012.12710.1038/embor.2012.127 ↗
37. 10.1111/j.1365-2559.1987.tb02609.x10.1111/j.1365-2559.1987.tb02609.x ↗
38. 10.1016/j.cellsig.2006.05.01910.1016/j.cellsig.2006.05.019 ↗
39. 10.1126/science.783914410.1126/science.7839144 ↗
40. 10.1164/rccm.201110-1826OC10.1164/rccm.201110-1826OC ↗